Panacea Index Logo

Command Palette

Search for a command to run...

Low-dose exogenous melatonin plus evening dim light and time in bed scheduling advances circadian phase irrespective of measured or estimated dim light melatonin onset time: preliminary findings.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
July 1, 2024
Leslie M Swanson et al. (10 authors)
Journal ArticleRandomized Controlled TrialHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine whether measuring dim light melatonin onset (DLMO) time improves the effectiveness of low-dose melatonin treatment combined with behavioral interventions (evening dim light and time in bed scheduling) for advancing circadian phase in adults with delayed sleep-wake phase disorder.

Results Summary

The study found that low-dose melatonin plus behavioral interventions improved circadian and sleep parameters, with no significant difference between groups using measured or estimated DLMO timing. However, the lack of group-by-visit interactions suggests that measuring DLMO may not provide additional benefits over estimation. The findings are preliminary and require larger-scale confirmation.

Population

40 adults with delayed sleep-wake phase disorder.

Effective Dosage

0.5 mg melatonin, timed 3 hours before measured DLMO or 5 hours before actigraphy-based sleep onset.

Duration

4 weeks.

Interactions

None mentioned.

Extracted Claims (3)
InterventionDirectionEndpointPopulationDosageImpactClaim #
low-dose melatonin treatment plus behavioral interventions (ie, evening dim light and time in bed scheduling)
increase
many circadian and sleep parameters
adults with delayed sleep-wake phase disorder
-
may improve
#1
low-dose exogenous melatonin plus evening dim light and time in bed scheduling
increase
circadian phase
adults with delayed sleep-wake phase disorder
-
advances
#2
0.5 mg melatonin timed to be administered either 3 hours before the DLMO (measured DLMO group) or 5 hours before sleep-onset time per actigraphy (estimated DLMO group), in conjunction with behavioral interventions
no change
any of the outcomes
adults with delayed sleep-wake phase disorder
-
no group-by-visit interactions
#3
Abstract

STUDY OBJECTIVES: The purpose of the present study was to preliminarily evaluate whether knowing the dim light melatonin onset (DLMO) time is advantageous when treating delayed sleep-wake phase disorder with low-dose melatonin treatment plus behavioral interventions (ie, evening dim light and time in bed scheduling). METHODS: In this randomized, controlled, double-blind trial, 40 adults with delayed sleep-wake phase disorder were randomly assigned to 4 weeks of 0.5 mg timed to be administered either 3 hours before the DLMO (measured DLMO group, n = 20) or 5 hours before sleep-onset time per actigraphy (estimated DLMO group, n = 20), in conjunction with behavioral interventions. The primary outcome was change in the DLMO (measured in-home). Secondary outcomes included sleep parameters per diary and actigraphy (sleep-onset and -offset times and total sleep time), Morningness-Eveningness Questionnaire, Multidimensional Fatigue Inventory, PROMIS-Sleep Disturbance, PROMIS-Sleep Related Impairment, and Pittsburgh Sleep Quality Index. Mixed-effects models tested for group differences in these outcome. RESULTS: After applying the Bonferroni correction for multiple comparisons (significant P value set at < .004), there were significant main effects for visit on all outcomes except for the Pittsburgh Sleep Quality Index and total sleep time per wrist actigraphy and diary. There were no group-by-visit interactions for any of the outcomes (P > .004). CONCLUSIONS: Scheduled low-dose melatonin plus behavioral interventions may improve many circadian and sleep parameters regardless of whether melatonin administration is scheduled based on estimated or measured DLMO. A larger-scale trial is needed to confirm these preliminary findings. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder; URL: https://clinicaltrials.gov/study/NCT03715465; Identifier: NCT03715465. CITATION: Swanson LM, de Sibour T, DuBuc K, et al. Low-dose exogenous melatonin plus evening dim light and time in bed scheduling advances circadian phase irrespective of measured or estimated dim light melatonin onset time: preliminary findings. J Clin Sleep Med. 2024;20(7):1131-1140.

Medical Subject Headings (MeSH)
HumansMelatoninMaleFemaleDouble-Blind MethodActigraphyMiddle AgedSleep Disorders, Circadian RhythmAdultCircadian RhythmTreatment OutcomeSurveys and QuestionnairesTime Factors
Study Links
Quality Scores
SafetyNot Assessed
Efficacy70/10
Quality80/10
Citation Metrics
Total Citations4
Citations/Year4.0
Research Impact Scores
APT Score0.50
Weight Score2.82
Normalized Score0.64
Related Supplements